# Lenvatinib Suppresses Angiogenesis through the Inhibition of both the VEGFR and FGFR Signaling Pathways

Published On: July 02, 2016 | Pages: 019 - 025

Author(s): Kenji Ichikawa, Saori Watanabe Miyano, Yusuke Adachi, Masahiro Matsuki, Kiyoshi Okamoto and Junji Matsui*

Lenvatinib mesilate (lenvatinib) is an oral multiple-receptor tyrosine kinase inhibitor that selectively inhibits the kinase activities of Vascular Endothelial Growth Factor Receptor (VEGFR) 1-3, Fibroblast Growth Factor Receptor (FGFR) 1-4, Platelet-Derived Growth Factor Receptor (PDGFR), KIT, and RET. The VEGFR and FGFR signaling pathways are the master regula ...

# A Novel Small-Molecule Integrin Antagonist Inhibits Cells Adhesion Followed By Anoikis in Endothelial Cells - A Comparative Analysis with Cilengitide

Published On: March 18, 2016 | Pages: 009 - 018

Author(s): Agnieszka Christenheit*, Petra Heffeter and Edgar Selzer

Background: Despite the crucial role of integrin receptors in cancer pathogenesis and massive efforts towards establishing clinically relevant drugs, to the present no effective integrin antagonist for the treatment of malignant diseases has been introduced into the clinic. Context and purpose of the study: The purpose of the study was to examine the cellular effec ...

# Case Report
Bortezomib in Anti-Cancer Activity: A Potential Drug

Published On: March 08, 2016 | Pages: 005 - 008

Author(s): Rajagopal Appavu* and Deepa Mohan

26S proteasome is an intracellular; ATP dependent enzymatic complex degrades ubiquitin-tagged proteins and maintains cellular homeostasis. The orderly degraded proteins including cyclins, caspases, Bcl-xL, p53, cell adhesion molecules are involved in cell-cycle progression, tumor suppression, DNA replication, inflammation, and apoptosis. So, proteasome inhibition is a...